Acalabrutinib is marketed under the brand name Calquence [1].
Who makes Calquence?
Calquence is developed and manufactured by AstraZeneca [1].
What is Calquence used to treat?
Calquence is approved for the treatment of adult patients with certain types of non-Hodgkin lymphoma (NHL) [1]. Specifically, it is used for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [1]. It is also indicated for previously treated CLL/SLL [1].
How does acalabrutinib work?
Acalabrutinib is a targeted therapy that works by inhibiting Bruton's tyrosine kinase (BTK) [1]. BTK is a protein that plays a role in the growth and survival of certain B cells, including cancerous B cells found in CLL and MCL [1]. By blocking BTK, acalabrutinib helps to reduce the number of these cancer cells [1].
When did Calquence receive FDA approval?
Calquence received its first FDA approval in October 2017 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. Subsequently, in June 2019, it received approval for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy [1]. Further approval was granted in March 2020 for previously untreated CLL/SLL [1].
What is the patent status for acalabrutinib?
Information on the patent exclusivity and expiration dates for acalabrutinib can be found on DrugPatentWatch.com [2]. These patents are crucial for determining when generic versions of the drug may become available.
How does acalabrutinib compare to other CLL/SLL treatments?
Acalabrutinib offers a targeted approach for CLL/SLL and MCL, differentiating it from traditional chemotherapy regimens. Clinical trials have compared acalabrutinib to other treatments, showing its efficacy and safety profile in various patient populations [1].
What are the common side effects of Calquence?
Common side effects reported with Calquence include fatigue, diarrhea, bruising, anemia, and low platelet count [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].